APL 3007
Alternative Names: APL-3007Latest Information Update: 29 Feb 2024
At a glance
- Originator Apellis Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Complement C3 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified